Viatris (VTRS) Net Equity Issued and Repurchased (2022 - 2026)
Viatris (VTRS) posted quarterly Net Equity Issued and Repurchased of $500000.0 for Q1 2026, down 16.67% year-over-year from $600000.0 in Q1 2025, and down 16.67% quarter-over-quarter from $600000.0 in Q4 2025.
Viatris (VTRS) Net Equity Issued and Repurchased (2022 - 2026) Analysis & Trends
Viatris' Net Equity Issued and Repurchased history runs 5 years deep, the most recent figure standing at $500000.0 for Q1 2026.
- In Q1 2026, Net Equity Issued and Repurchased fell 16.67% year-over-year to $500000.0; the TTM figure through Mar 2026 stood at $2.5 million (changed 0.0% YoY), while the FY2025 annual figure was $2.6 million, up 4.0% from the prior year.
- Net Equity Issued and Repurchased for Q1 2026 stood at $500000.0, down from $600000.0 in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $1.8 million in Q3 2022, with the low at $500000.0 in Q1 2026.
- The 5-year median for Net Equity Issued and Repurchased is $700000.0 (2022), against an average of $750000.0.
- The sharpest annual moves came in 2023 and 2025: Net Equity Issued and Repurchased plunged 55.56% in 2023, then rose 16.67% in 2025.
- Viatris' Net Equity Issued and Repurchased stood at $800000.0 in 2022, then retreated by 25.0% to $600000.0 in 2023, then changed by 0.0% to $600000.0 in 2024, then changed by 0.0% to $600000.0 in 2025, then fell by 16.67% to $500000.0 in 2026.
- Business Quant data shows VTRS's Net Equity Issued and Repurchased at $500000.0 in Q1 2026, $600000.0 in Q4 2025, and $700000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.78 Bn | 42.82 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.24 Bn | 39.59 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.66 Bn | 29.98 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.72 Bn | 22.92 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.34 Bn | 19.68 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.80 Bn | 17.91 Bn | 1.46 Bn | 700,000.00 |
| 7 | Neurocrine Biosciences | 15.64 Bn | 15.25 Bn | 935.80 Mn | 84.80 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - | - |
| 10 | Alkermes | 8.25 Bn | 7.59 Bn | 397.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 700,000.00 |
| Jun 30, 2026 | 700,000.00 |
| Mar 31, 2026 | 500,000.00 |
| Mar 31, 2026 | 500,000.00 |
| Dec 31, 2025 | 600,000.00 |
| Dec 31, 2025 | 600,000.00 |
| Sep 30, 2025 | 700,000.00 |
| Sep 30, 2025 | 700,000.00 |
| Jun 30, 2025 | 700,000.00 |
| Jun 30, 2025 | 700,000.00 |
| Mar 31, 2025 | 600,000.00 |
| Mar 31, 2025 | 600,000.00 |
| Dec 31, 2024 | 600,000.00 |
| Dec 31, 2024 | 600,000.00 |
| Sep 30, 2024 | 600,000.00 |
| Sep 30, 2024 | 600,000.00 |
| Jun 30, 2024 | 700,000.00 |
| Jun 30, 2024 | 700,000.00 |
| Mar 31, 2024 | 600,000.00 |
| Mar 31, 2024 | 600,000.00 |